Stock-Based Compensation (Tables)
|
3 Months Ended |
Dec. 31, 2024 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Awards Outstanding |
The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, 2024 | | | 2013 Plan | | 2021 Plan | | Inducement Awards | | Total | | Granted and outstanding awards: | | | | | | | | | | Options | | 1,248,038 | | | 32,151 | | | 602,939 | | | 1,883,128 | | | Restricted stock units | | 1,607,885 | | | 2,943,382 | | | 512,507 | | | 5,063,774 | | | Total | | 2,855,923 | | | 2,975,533 | | | 1,115,446 | | | 6,946,902 | |
|
| Schedule of Share-Based Payment Arrangement, Expensed |
The following table summarizes stock-based compensation expenses included in operating expenses: | | | | | | | | | | | | | | Three Months Ended December 31, | | | 2024 | | 2023 | | | (in thousands) | | | | | | | | Research and development | $ | 6,846 | | | $ | 7,823 | | | | General and administrative | 7,329 | | | 9,862 | | | | Total | $ | 14,175 | | | $ | 17,685 | | |
|
| Schedule of Summarized Information about Stock Options |
The following table presents a summary of the stock option activity for the three months ended December 31, 2024: | | | | | | | | | | | | | | | | | | | | | | | | | Shares | | Weighted-
Average
Exercise
Price
Per Share | | Weighted-
Average
Remaining
Contractual
Term (Years) | | Aggregate
Intrinsic
Value | Outstanding at September 30, 2024 | 1,978,516 | | $ | 23.39 | | | | | | | Granted | — | | — | | | | | | | Cancelled or expired | (25,882) | | 40.20 | | | | | | | Exercised | (69,506) | | 9.06 | | | | | | Outstanding at December 31, 2024 | 1,883,128 | | $ | 23.69 | | | 3.3 | | $ | 12,408,737 | | Exercisable at December 31, 2024 | 1,882,710 | | $ | 23.68 | | | 3.3 | | $ | 12,408,737 | |
|
| Schedule of Share Activity Related to RSUs |
The following table summarizes the activity of the Company’s RSUs: | | | | | | | | | | | | | Number of
RSUs | | Weighted-
Average
Grant
Date
Fair Value
Per Share | Outstanding at September 30, 2024 | 4,913,312 | | $ | 49.61 | | | Granted | 493,148 | | 20.20 | | | Vested | (209,122) | | 62.88 | | | Forfeited | (133,564) | | 35.12 | | Outstanding at December 31, 2024 | 5,063,774 | | $ | 46.58 | |
|